Results 311 to 320 of about 574,104 (383)

FOXM1 Protects Against Myocardial Ischemia‐Reperfusion Injury in Rodent and Porcine Models by Suppressing MKRN1‐Dependent LKB1 Ubiquitination

open access: yesAdvanced Science, EarlyView.
FOXM1 maintains mitochondrial bioenergetic function by inhibiting MKRN1‐mediated ubiquitination of LKB1 in cardiomyocytes. Loss of FOXM1 in cardiomyocytes results in upregulation of MKRN1, which enhances LKB1 ubiquitination and disrupts AMPK signaling and energy metabolism pathways. Conversely, FOXM1 overexpression preserves mitochondrial bioenergetics
Shuai Song   +17 more
wiley   +1 more source

Solving the Amyloid Paradox: Unveiling the Complex Pathogenicity of Amyloid Fibrils

open access: yesAggregate, EarlyView.
This review addresses the gap between strong evidence for the involvement of amyloid fibrils in neurodegeneration and the failure of anti‐amyloid therapies, a phenomenon herein termed the “amyloid paradox.” To address this paradox, we provide a comprehensive summary of the current understanding of fibrils' pathogenic properties and mechanisms ...
Maksim I. Sulatsky   +3 more
wiley   +1 more source

The Lysine Deprotonation Mechanism in a Ubiquitin Conjugating Enzyme. [PDF]

open access: yesJ Phys Chem B
Wathan AJ   +3 more
europepmc   +1 more source

Harnessing the Biological Responses Induced by Nanomaterials for Enhanced Cancer Therapy

open access: yesAggregate, EarlyView.
Nanomaterial (NM)‐induced toxicity can be strategically repurposed for cancer therapy. This review summarizes the mechanism by which NMs selectively activate specific cellular processes to regulate cell fate independently. We also discussed how NMs‐induced biological responses can be leveraged as therapeutic strategies for cancer treatment.
Liting Wang   +6 more
wiley   +1 more source

Repurposing With Purpose: Treatment of Bachmann–Bupp Syndrome With Eflornithine and Implications for Other Polyaminopathies

open access: yesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Rare diseases impact approximately 1 in 10 people worldwide, and yet, less than 5% of all rare diseases currently have an approved treatment option available. This is due to many challenges unique to rare diseases, including small, diverse patient populations, the cost of drug development that is not proportionate to the number of patients who
Caleb P. Bupp   +7 more
wiley   +1 more source

Midnolin Ubiquitination is Required for its Proteasome-Mediated Degradation. [PDF]

open access: yesMedComm (2020)
He J   +9 more
europepmc   +1 more source

Longitudinal Analysis of Neuroradiological Biomarkers for Fragile X‐Associated Tremor/Ataxia Syndrome and Implications for Clinical Trials

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to show the capacity of structural brain magnetic resonance imaging (MRI) measures to serve as monitoring biomarkers for Fragile X‐Associated Tremor/Ataxia Syndrome (FXTAS). Methods From 2 longitudinal studies of male FMR1 premutation carriers, 2 brain MRI scans were selected from each participant, collected ...
David Hessl   +6 more
wiley   +1 more source

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

open access: yesAngewandte Chemie, EarlyView.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker   +3 more
wiley   +2 more sources

Midnolin inhibits coronavirus proliferation by degrading viral proteins. [PDF]

open access: yesJ Virol
Wang Y   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy